FierceBiotechOriginal article
{"a":[{"_":"Biogen defends anti-tau drug after stock slides on Alzheimer’s readout","$":{"href":"/biotech/biogen-defends-anti-tau-drug-after-stock-slides-alzheimers-readout","hreflang":"en"}}]}
Phase 2MixedNegative
AI Analysis
Summary
Biogen's anti-tau Alzheimer's drug achieved Phase 2 efficacy results showing cognitive decline slowing comparable to approved medicines, but the readout triggered a significant stock decline prompting management to defend the candidate on an investor call.
Clinical Trial Data
Phase
2
Primary Endpoint
Met
Outcome Details
Slowed cognitive decline on par with approved medicines but sparked significant stock decline
Importance:6/10
Sentiment:
-0.40
Alzheimer's diseaseanti-tauPhase 2stock declineinvestor defense
Related Companies
Read the original article
Published by FierceBiotech on July 14, 2026 1:48 PM